Pmv Pharmaceuticals Inc (PMVP) - Total Liabilities
Based on the latest financial reports, Pmv Pharmaceuticals Inc (PMVP) has total liabilities worth $10.57 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore investment intensity of Pmv Pharmaceuticals Inc to see how much of total assets are deployed in long-term investments.
Pmv Pharmaceuticals Inc - Total Liabilities Trend (2018–2025)
This chart illustrates how Pmv Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Pmv Pharmaceuticals Inc (PMVP) total assets.
Pmv Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Pmv Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Broadway Financial Corporation
NASDAQ:BYFC
|
USA | $1.30 Billion |
|
Konka Group Co Ltd
SHE:200016
|
China | HK$25.60 Billion |
|
Kumpulan Perangsang Selangor
KLSE:5843
|
Malaysia | RM356.52 Million |
|
Hainan Airlines Co Ltd B
SHG:900945
|
China | $148.78 Billion |
|
5E Advanced Materials Inc
AU:5EA
|
Australia | AU$5.10 Million |
|
Mackolik Internet Hizmetleri Ticaret A.S.
IS:MACKO
|
Turkey | TL191.45 Million |
|
SG&G Corporation
KQ:040610
|
Korea | ₩70.80 Billion |
|
Silvercrest Asset Management Group Inc
NASDAQ:SAMG
|
USA | $81.72 Million |
Liability Composition Analysis (2018–2025)
This chart breaks down Pmv Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Pmv Pharmaceuticals Inc balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.70 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pmv Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pmv Pharmaceuticals Inc (2018–2025)
The table below shows the annual total liabilities of Pmv Pharmaceuticals Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $11.85 Million | -22.08% |
| 2024-12-31 | $15.21 Million | -42.53% |
| 2023-12-31 | $26.46 Million | +8.99% |
| 2022-12-31 | $24.28 Million | +5.52% |
| 2021-12-31 | $23.01 Million | +258.95% |
| 2020-12-31 | $6.41 Million | -96.31% |
| 2019-12-31 | $173.51 Million | +58.31% |
| 2018-12-31 | $109.60 Million | -- |
About Pmv Pharmaceuticals Inc
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases. The company was formerly known as PJ Pharmaceuticals, Inc. an… Read more